Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of ASP5354 in Renal Impairment
NCT05495581Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2022
- Primary completion
- Apr 2023
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 2
01
Overview
Phase 1, open-label trial of pudexacianinium chloride in ureteral injury (4 arms), sponsored by Astellas Pharma. Primary endpoints: Area under the concentration-time curve from time of dosing extrapolated to time infinity up to 3 days, Area under concentration-time curve from the time of dosing to the last measurable concentration up to 3 days and 7 more. Started Aug 2022; status: completed.
02
Drugs
pudexacianinium chloride
03
Conditions
ureteral injury
Beyond the preview
Go deeper on NCT05495581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05495581.